Biodistribution and Dosimetry of 99mTc-Duramycin

• Status: Completed
• Trial end date: 2021-12-14
• Target enrollment: 0
• Participant gender: All

Summary

Conduct a first-in-human study in healthy volunteers to show safety, biodistribution and dosimetry of [99mTc]Duramycin.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Antwerp
• Collaborator: Molecular Targeting Technologies, Inc.

Criteria

Inclusion Criteria:

• Males (n=4) or females (n=4) age 18 years or older

• Stated willingness to comply with all study procedures and availability for the duration of the study.

• Ability to give study-specific written informed consent.

Exclusion Criteria:

• Pregnant or lactating females (positive pregnancy test)

• Metal implants (e.g. pacemakers, osteosynthesis material)

• Body weight > 100 kg

• Severe claustrophobia

• Abnormal kidney or liver function tests

• Unable to comply with study requirements